Is doxycycline effective for skin and skin structure infections (SSTIs)? Recent evidence highlights its role in selected outpatient infections, while emphasizing targeted antibiotic use.
Doxycycline remains a practical oral option for selected skin and skin structure infections (SSTIs), particularly when methicillin-resistant Staphylococcus aureus (MRSA) is suspected or confirmed. A recent report highlights its role in treating purulent SSTIs and its suitability for outpatient care.
A member of the tetracycline class, doxycycline has been used for more than six decades. Its high oral bioavailability and activity against S. aureus, including MRSA, have supported its continued clinical use.
Evidence also indicates that oral tetracyclines can be considered for purulent SSTIs, alongside other established therapies such as trimethoprim-sulfamethoxazole and clindamycin (1✔ ✔Trusted Source
Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline
Advertisement
What Are Skin and Skin Structure Infections (SSTIs)?
Skin and skin structure infections (SSTIs) encompass a broad range of bacterial infections involving the skin and underlying tissues. They include conditions such as cellulitis, abscesses, furuncles, carbuncles and other superficial or deeper infections.
A 2025 review published in Current Opinion in Infectious Diseases notes that acute bacterial skin and skin structure infections (ABSSSIs) continue to represent an important clinical challenge, while newer antimicrobial options and approaches are changing the treatment landscape (2✔ ✔Trusted Source
The future approach for the management of acute bacterial skin and skin structure infections
The type of infection is important when selecting an antibiotic because purulent and non-purulent SSTIs may have different causative organisms. S. aureus, including MRSA, is an important pathogen in purulent infections, while streptococci are commonly associated with non-purulent cellulitis.
Advertisement
Why Is Doxycycline Considered for Outpatient SSTIs?
Doxycycline is particularly relevant when MRSA is suspected because of its activity against susceptible strains of the organism. Doxycycline has high oral bioavailability of approximately 90–100% and a relatively favorable safety profile, making it a practical oral option for appropriate adult outpatients.
The report also cites guideline-supported use of doxycycline for purulent SSTIs and notes that clinical studies have demonstrated its effectiveness in selected patients. The article highlights a commonly referenced regimen of a 200 mg loading dose on day one followed by 100 mg every 12 hours for 5–10 days, although treatment should always be determined by a clinician based on the individual infection and patient characteristics.
Advertisement
2025 Evidence Continues to Examine Doxycycline’s Role
A randomized clinical trial provides additional evidence on doxycycline for uncomplicated suppurative skin and skin structure infections (3✔ ✔Trusted Source
A Randomized Trial of Doxycycline vs. Trimethoprim Sulfamethoxazole (TMP-SMX) for Uncomplicated Skin and Skin Structure Infections (SSSIs)
).The multicenter study compared doxycycline with trimethoprim-sulfamethoxazole in 269 patients receiving outpatient treatment after adequate source control. Early clinical response was similar between the doxycycline and trimethoprim-sulfamethoxazole groups, while responses at the end of treatment and one-month follow-up were also not significantly different.
The researchers concluded that doxycycline appeared to be a safe and effective alternative to trimethoprim-sulfamethoxazole for adults and children older than eight years with suppurative uncomplicated SSTIs who had undergone appropriate source control.
These findings are relevant because most uncomplicated suppurative SSTIs can be managed in the outpatient setting, making effective oral antibiotic options particularly important.
But Doxycycline Is Not Appropriate for Every SSTI
The evidence also highlights why doxycycline should not be viewed as a universal antibiotic for all skin infections.
New study examining culture-negative acute bacterial skin and skin structure infections reported higher clinical failure rates among patients treated with doxycycline compared with cephalexin or trimethoprim-sulfamethoxazole (4✔ ✔Trusted Source
Doxycycline is Inferior to Cephalexin and Sulfamethoxazole/Trimethoprim (SMX/TMP) for the Treatment of Culture Negative Acute Bacterial Skin and Skin Structure Infections (ABSSSIs)
Go to source). In the analysis, clinical failure occurred in 31.3% of patients receiving doxycycline, compared with 16.8% receiving cephalexin and 18.5% receiving trimethoprim-sulfamethoxazole.
The findings reinforce the importance of correctly identifying the type of SSTI before selecting an antibiotic. In particular, prescribing an antibiotic primarily for MRSA coverage may not be appropriate when the infection is non-purulent and streptococcal infection is more likely.
Antibiotic Resistance Is Another Consideration
Doxycycline’s usefulness against MRSA also depends on antimicrobial susceptibility. Resistance patterns can vary by location and bacterial strain, making local susceptibility data and microbiological testing important when available.
Research presented in Open Forum Infectious Diseases examined the use of doxycycline for MRSA SSTIs in the setting of tetracycline resistance (5✔ ✔Trusted Source
The Use of Doxycycline for MRSA SSTIs in the Setting of Tetracycline Resistance
Go to source).The study focused on the possibility of inducible doxycycline resistance among tetracycline-resistant MRSA isolates and highlighted the need to consider resistance mechanisms when doxycycline is being used to treat MRSA SSTIs.
This is particularly relevant as antimicrobial resistance continues to complicate the management of bacterial skin infections.
Source Control Remains Important
Antibiotics are not the only component of SSTI management. For patients with abscesses and other purulent infections, appropriate source control, including incision and drainage when indicated, can be essential.
The randomized trial evaluating doxycycline and trimethoprim-sulfamethoxazole specifically included patients who had received adequate source control, demonstrating that antibiotic effectiveness should be considered alongside appropriate management of the underlying infection.
What the Latest Evidence Means for Doxycycline
Taken together, the evidence presents a balanced picture of doxycycline’s role in skin and skin structure infections (SSTIs).
For clinicians, the key consideration remains the same: identify the type of SSTI, assess the likely pathogen and resistance profile, determine whether source control is required, and then select the most appropriate antimicrobial therapy.
Doxycycline therefore remains a useful tool in outpatient SSTI management, but its value is greatest when its antibacterial spectrum and clinical profile match the infection being treated.
References:
- Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline – (https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.2625)
- The future approach for the management of acute bacterial skin and skin structure infections – (https://pubmed.ncbi.nlm.nih.gov/39831591/)
- A Randomized Trial of Doxycycline vs. Trimethoprim Sulfamethoxazole (TMP-SMX) for Uncomplicated Skin and Skin Structure Infections (SSSIs) – (https://pmc.ncbi.nlm.nih.gov/articles/PMC12793100/)
- Doxycycline is Inferior to Cephalexin and Sulfamethoxazole/Trimethoprim (SMX/TMP) for the Treatment of Culture Negative Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) – (https://pmc.ncbi.nlm.nih.gov/articles/PMC12792333/)
- The Use of Doxycycline for MRSA SSTIs in the Setting of Tetracycline Resistance –(https://pmc.ncbi.nlm.nih.gov/articles/PMC11776787/)
Source-Medindia